Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment
Betsy Goodfellow | January 18, 2024 | News story | Medical Communications | Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial
Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. The study aims to assess quemliclustat, an investigational small molecule CD73 inhibitor, plus chemotherapy, with or without zimberelimab, for the treatment of patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
The results are intended to be presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
Results from the trial demonstrated that treatment with quemliclustat resulted in a 47% reduction in the risk of death and a 5.9 month increase in median overall survival.
Zev A Wainberg MD MSc, co-director of the GI Oncology Programme at the University of California Los Angeles, US, and principal investigator on this trial, commented: “A quemliclustat-based regimen appears to meaningfully prolong survival compared to what we typically observe in patients with mPDAC who receive chemotherapy alone, the standard of care for more than 30 years. CD73 is highly expressed on pancreatic cancer cells, and I am encouraged to see early evidence that inhibiting CD73 with a small molecule has the potential to improve outcomes for people with mPDAC, without an observed clinically meaningful increase in toxicity, when combined with standard of care chemotherapy relative to historical data for chemotherapy alone.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
